S
LYRA

SignatureFD’s LYRA THERAPEUTICS INC LYRA Stock Holding History

SignatureFD’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10
Closed -$1.96K – 3208
2023
Q3 		$1.96K Hold
10
– – ﹤0.01% 2772
2023
Q2 		$2.06K Hold
10
– – ﹤0.01% 2802
2023
Q1 		$1K Hold
10
– – ﹤0.01% 2993
2022
Q4 		$1.57K Hold
10
– – ﹤0.01% 2875
2022
Q3 		$3K Buy
+10
New +$2.96K ﹤0.01% 2657

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SignatureFD's LYRA Position: Q4 2023 in Review

SignatureFD sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2023, closing a stake of 10 shares — an estimated $1.96K sold.

SignatureFD first reported a position in LYRA in Q3 2022 and held it in 5 quarters. The position peaked at $3K in Q3 2022. 60 funds tracked by Wall St. Rank hold LYRA as of Q4 2023.

  • SignatureFD reported no remaining LYRA THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • SignatureFD sold 10 LYRA THERAPEUTICS INC shares in Q4 2023, an estimated $1.96K.
  • SignatureFD first reported a position in LYRA THERAPEUTICS INC in Q3 2022 and held it in 5 quarters.
  • SignatureFD's LYRA THERAPEUTICS INC position peaked at $3K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.